ODYSSEY trial

Study / ResearchMentioned in 1 video

A cardiovascular outcome trial for Alirocumab (a PCSK9 inhibitor) in patients with recent acute coronary syndrome, showing a 15% reduction in major adverse cardiovascular events.

Videos Mentioning ODYSSEY trial

230 ‒ Cardiovascular disease in women: prevention, risk factors, lipids, and more

230 ‒ Cardiovascular disease in women: prevention, risk factors, lipids, and more

Peter Attia MD

A cardiovascular outcome trial for Alirocumab (a PCSK9 inhibitor) in patients with recent acute coronary syndrome, showing a 15% reduction in major adverse cardiovascular events.